General Proximity pioneers next-generation medicines by controlling biological processes through proximity. Redefining the future of medicine for all humankind. Backed by Y Combinator and Felicis.
About the role
We are seeking an exceptional DMPK expert to join and lead our drug metabolism and pharmacokinetics function. This is a hands-on, high-impact role in which you will design and execute DMPK studies across our small molecule portfolio, interpret and communicate data to project teams, and serve as a key DMPK contributor in cross-functional settings.
What they're looking for
- PhD in pharmacokinetics, pharmaceutical sciences, or a related discipline
- A minimum of 3 years of industry experience in DMPK, spanning drug discovery and development, with a track record of contributing to small molecule programs
- Demonstrated ability to work independently and collaborate effectively within cross-functional project teams
- Hands-on expertise in in vitro ADME and in vivo PK, with the ability to translate data into actionable drug discovery insights
- Proficiency in PK data analysis (Phoenix WinNonlin or equivalent) and familiarity with PBPK/PK-PD modeling platforms (Simcyp, GastroPlus, or equivalent)
- Experience contributing to IND-enabling DMPK studies and authoring study reports
More about this role
tl;dr
General Proximity is a seed-stage startup developing the next generation of induced proximity medicines (IPMs). Our OmniTAC drug discovery engine furnishes molecules that co-opt existing cellular machinery to overcome therapeutic challenges, which have remained unapproachable to other modalities for decades.
We are seeking a first-rate DMPK expert to help us pioneer this uncharted frontier of drug discovery.
Our Story
A long-standing challenge in drug discovery is the development of molecules capable of modulating difficult or "undruggable" targets. Disease-causing proteins can be dysfunctional in many different ways, but our armamentarium for fixing them is quite limited. The most common mechanism of action for FDA-approved drugs is inhibition [1] , but there are many other possible perturbation types whose potential remains unrealized.
General Proximity is a seed-stage drug discovery company developing a novel platform technology to solve this problem. We make bifunctional drugs that induce the modification of drug targets by existing cellular machinery (rather than through direct modulation by the drug, the classical approach).
Historically, the development of...
Browse similar: Startup jobs · San Francisco Bay Area